What caused 4597.T stock to fall pre-market to JPY 29.00?

Pre-market selling on 24 Mar 2026 reflects heavy volume of **49,046,600** shares and profit-taking after recent gains. No single public catalyst was released; traders are reacting to clinical and earnings timing ahead of the 20 May 2026 report.

What is Meyka AI's near-term forecast for 4597.T stock?

Meyka AI's forecast model projects a monthly price of **JPY 32.39**, implying **11.69%** upside from **JPY 29.00**, and a yearly model of **JPY 25.66**, implying **11.50%** downside. Forecasts are model-based projections and not guarantees.

How do fundamentals affect 4597.T stock outlook?

Solasia shows strong liquidity with current ratio **6.06** and cash per share **4.90**, but negative EPS **-8.96** and weak margins raise valuation risk. The balance of cash versus operating losses shapes the medium-term outlook.

Which technical levels matter for 4597.T stock today?

Key levels: intraday low **JPY 29.00**, recent support **JPY 27.00**, 50-day average **JPY 30.78**, and Bollinger middle **JPY 32.30**. A move above **JPY 32.30** would ease short-term bearish pressure.

JP Stocks

4597.T Solasia Pharma (JPX) JPY 29.00 pre-market 24 Mar 2026: heavy volume

ByHuzaifa Zahoor March 24, 2026March 24, 2026

4597.T stock fell to JPY 29.00 in pre-market trading on 24 Mar 2026, driven by a surge in volume to 49,046,600 shares. The move marks a 9.38% one-day decline from yesterday’s close of JPY 32.00, and places Solasia Pharma K.K. (4597.T) among the JPX most active names this session. Traders are pricing fresh risk around upcoming catalysts, while liquidity at 49.05 million shares hints at strong short-term interest in the Healthcare sector.